Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Chronic Weight Management (Wegovy ): This formulation is approved for adults and adolescents (aged 12 and older) with obesity (BMI 30) or who are overweight (BMI 27) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Ashrafi S, Shapouri R, Mahdavi M
In July of this year, a bill entitled the Treat and Reduce Obesity Act of 2023 was introduced in the Senate with the explicit goal of lifting Medicares coverage exclusion for weight loss products, arguing that obesity increases the risk of multiple chronic conditions and thus costs the government billions of dollars
[45] [46] The FDA approved the first generic liraglutide in December 2024, and granted the approval to Hikma Pharmaceuticals USA [13] Controversy [edit] In 2010, Novo Nordisk breached the Association of the British Pharmaceutical Industry's code of conduct by failing to provide information about side effects, and by promoting it prior to being granted market authorization
